Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Apollo Hospitals partners with Ainnova Tech for AI-driven disease detection
The solutions will enhance the early and precise detection of various conditions. Credit: raker/Shutterstock. · Hospital Management · raker/Shutterstock.

In This Article:

Apollo Hospitals has announced a strategic collaboration with Ainnova Tech, a healthcare technology company, to integrate artificial intelligence (AI) into disease detection and prediction.

This partnership has led to Ainnova securing an exclusive license for advanced AI algorithms, validated with more than 2.3 million data points, for its Vision AI platform.

These AI solutions are designed to enhance the early and precise detection of various conditions, including liver fibrosis, cardiovascular and chronic kidney diseases, type 2 diabetes, and lung abnormalities.

Last month, Avant Technologies and Ainnova formed a joint venture, Ai-Nova Acquisition (AAC), and signed a global development and licensing deal.

With AAC now holding a global licence to develop and market Ainnova's technology, the collaboration with Apollo strengthens the venture's global efforts to advance AI in healthcare.

These AI-driven diagnostics are set to be available on the Vision AI platform across the Americas, with the first commercial pilot programmes launching soon.

With a population of over 200 million, Brazil is set to expand, having met the regulatory requirements of Brazil's Health Regulatory Agency, ANVISA.

Integrating the AI-powered solution aims to enhance chronic disease management by adding value to patient care.

These tools offer a comprehensive preventive health assessment and will enable early referrals from primary care or community health services to specialised medical professionals.

Apollo and Ainnova aim to further develop and deploy AI-driven healthcare solutions, with additional innovations expected to be introduced shortly.

Earlier this month, Apollo Hospitals signed a term sheet with Ion Beam Applications (IBA) for the procurement of one ProteusONE compact proton therapy solution.

"Apollo Hospitals partners with Ainnova Tech for AI-driven disease detection" was originally created and published by Hospital Management, a GlobalData owned brand.


 


The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.